April-June, Volume 7, Number
In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people. The pathways for developing these products have key similarities as well as differences—and as the same drugs advance for treatment and PrEP, it will be key to communicate these. We hope this issue of Px Wire is a start.
Advocates who want to learn more can listen to a recent webinar on long-acting injectables.
This quarter’s issue also explores progress in implementing oral PrEP. It's been nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP. In that time we've seen an increasing number of people begin to view the strategy as an important niche intervention that could save lives and should be promoted more widely. For more information on PrEP, visit www.prepwatch.org.
Download graphics from the latest issue of Px Wire:
Px Wire Archive: View Px Wire issues starting from January 2008